SNU-407 cells were treated with a combination of varying concentrations of MRTX1133 with varying concentrations of either afatinib, sapitinib, or pelitinib for 72 hours. Absorbances were normalized to DMSO control for % viability. The attached files were compiled in data format from n=2 data sets (6 data points total for each combination) and uploaded to SynergyFinder+ with % viability chosen as response.
LS513 cells were treated with a combination of varying concentrations of MRTX1133 with varying concentrations of either afatinib, sapitinib, or pelitinib for 72 hours. Absorbances were normalized to DMSO control for % viability. The attached files were compiled in data format from n=2 data sets (6 data points total for each combination) and uploaded to SynergyFinder+ with % viability chosen as response.